SCHEMBL4472619

SCHEMBL4472619

CN(C)c1ccc(NC(=O)Oc2ccc3cc(-c4nc(-c5ccccc5)[nH]c4-c4ccncc4)ccc3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 1/20 0.53
TEK Q02763 6/20 0.52
RAF1 P04049 5/20 0.52
MAPK14 Q16539 6/20 0.51
MAPK13 O15264 3/20 0.51
MAPK12 P53778 3/20 0.51
MAPK11 Q15759 3/20 0.51
ALOX5 P09917 3/20 0.50
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
GFER P55789 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
BRAF P15056 3/20 0.48
CSNK1D P48730 1/20 0.48
CSNK1E P49674 1/20 0.48
BRDT Q58F21 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475402 0.91 RAF1 (0.56) TEKRAF1MAPK14MAPK13MAPK12
SCHEMBL4490139 0.88 RAF1 (0.69) TEKRAF1MAPK14MAPK13MAPK12
SCHEMBL4468049 0.88 KDM4E (0.45) NOX1TEKRAF1MAPK14MAPK13
SCHEMBL4467742 0.84 RAF1 (0.64) TEKRAF1MAPK14MAPK13MAPK12
SCHEMBL4468775 0.82 MAPT (0.53) TEKRAF1MAPK14MAPK13MAPK12
SCHEMBL4467748 0.80 ALOX5 (0.52) TEKRAF1MAPK14MAPK13MAPK12
SCHEMBL12152249 0.77 NOX1 (0.56) NOX1RAF1ALOX5KDM4EMEN1
SCHEMBL4483579 0.76 ALOX5 (0.49) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL6466096 0.75 RAF1 (0.68) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL4721236 0.74 RAF1 (0.72) TEKRAF1MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569593-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-08-04 US claimed
EP-1670780-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-12-17 EP claimed
EP-1670780-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-06-21 EP claimed
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-09-22 US claimed
WO-2005030151-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (US) 2005-04-07 WO claimed
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; IRM LLC (BM) 2009-10-15 US disclosed
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; IRM LLC (BM) 2009-10-15 US disclosed
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; IRM LLC (BM) 2009-10-15 US disclosed
US-7569593-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-08-04 US disclosed
US-7569593-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-08-04 US disclosed
US-7569593-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-08-04 US disclosed
EP-1670780-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-12-17 EP disclosed
EP-1670780-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-06-21 EP disclosed
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-09-22 US disclosed
WO-2005030151-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; PDGFRA, RAF1, FLT1 NOX1 689/4885TEK 73/4885RAF1 2/4885
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors LCK, RAF1, MAP3K1 NOX1 691/4885TEK 115/4885RAF1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.